NPC(SH:600713) Cai Jing Wang·2025-09-18 13:43Core Insights - The company held a performance briefing for the first half of 2025, highlighting a wholesale business gross margin of approximately 5.5% and a higher gross margin of around 15% for its e-commerce business [1] - The strategic focus includes SPD business and "Internet+" initiatives in pharmaceuticals, covering B2B, B2C, O2O, special medical foods, and radioactive drugs [1] - Revenue from emerging businesses reached approximately 3.3 billion yuan, accounting for about 12% of total revenue in the first half of 2025 [1] Business Performance - The company has been actively cultivating its "Internet+" business alongside traditional pharmaceutical wholesale and retail operations [1] - New service models such as "Internet+ Pharmaceutical Services" and "Internet+ Traditional Chinese Medicine Services" have been launched, along with innovations in O2O and B2C e-commerce retail formats [1] - For the first half of 2025, emerging business revenue was 851 million yuan, achieving progress towards the target of at least 28% growth compared to 2024 [1]